“The Penn Gene Therapy Program (GTP) is at the frontier of developing novel gene therapies that offer promising treatment options for patients with incurable diseases. I am excited to be working here because GTP is highly collaborative and combines the fast-paced approach to the science of a small biotech company in the setting of a world-class academic medical center. I feel very privileged to be working with Dr. Jim Wilson and all the dedicated team members at GTP.”
As the Chief Medical Officer, Fabian leads the clinical development at GTP, which involves working closely with cross-functional teams and external partners. Prior to GTP, Fabian was the Vice President at Rocket Pharmaceuticals and led an AAV gene therapy program. He previously worked at Novartis, where he had an integral role in the approval of Entresto for the treatment of adult and pediatric heart failure. Fabian was also a clinical leader in Experimental Medicine and Clinical Cardiovascular for five years at Merck.
Prior to industry, Fabian was on the faculty at UCLA in the departments of Medicine, Pediatrics, and Molecular, Cellular & Integrative Physiology. Before UCLA, Fabian was at Penn for 8 years completing his Internal Medicine and Cardiology training as well as postdoctoral training with Dr. Jonathan Epstein. Fabian received his MD-PhD from Yale and his BA from Harvard.